<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104467</url>
  </required_header>
  <id_info>
    <org_study_id>11764A</org_study_id>
    <nct_id>NCT01104467</nct_id>
  </id_info>
  <brief_title>Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke</brief_title>
  <acronym>DIAS-J</acronym>
  <official_title>Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundbeck Japan K. K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lundbeck Japan K. K.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether desmoteplase is safe and tolerated when given
      to Japanese patients with acute ischemic stroke
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a safety and tolerability study of desmoteplase in Japanese patients with acute
      ischemic stroke. The study will test two doses
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of desmoteplase doses of 70 µg/kg and 90 µg/kg in Japanese patients with acute ischemic stroke as measured by the presence of symptomatic intracranial haemorrhage (sICH) within 72 hours after IMP</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical improvement at Day 90 after administration of Investigational Medicinal Product (IMP) as measured by modified Rankin Scale (mRS)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical improvement at Day 7 and 30 after administration of IMP as measured by modified Rankin Scale (mRS)</measure>
    <time_frame>Day 7 and Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate recanalisation at 18±6 hr after administration of IMP</measure>
    <time_frame>18±6 hr after administration of IMP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate change in infarct size at 18±6 hr relative to pre-treatment infarct size</measure>
    <time_frame>18±6 hr after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of desmoteplase</measure>
    <time_frame>0.5 - 9 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunogenicity of desmoteplase</measure>
    <time_frame>Day 7, Day 30, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the predictive value of different volumes of absolute mismatch for the clinical response and other objectives</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Desmoteplase 70 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmoteplase 90 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmoteplase</intervention_name>
    <description>1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)</description>
    <arm_group_label>Desmoteplase 70 µg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmoteplase</intervention_name>
    <description>1 bolus injection of desmoteplase 90 µg/kg (IV)</description>
    <arm_group_label>Desmoteplase 90 µg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 bolus injection of placebo IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of acute ischemic stroke

          -  Provided Informed Consent

          -  Male or female

          -  Aged between 20 and 85 years inclusive

          -  Treatment within 3-9 hr after onset of stroke symptoms.

          -  NIHSS score of 4-24 inclusive with clinical signs of hemispheric infarction

          -  Must receive IMP within 60 minutes after brain imaging

          -  Cerebral artery occlusion or high-grade stenosis in MCA

        Exclusion Criteria:

          -  Pre-stroke mRS score of &gt;1

          -  Previously exposed to desmoteplase

          -  Scores &gt;2 on NIHSS question 1a indicating coma

          -  History or clinical presentation of ICH, subarachnoid haemorrhage (SAH),
             arterio-venous malformation (AVM), moyamoya disease, cerebral neoplasm or aneurysm

          -  Current use of oral anticoagulants and a prolonged prothrombin time (INR &gt;1.6)

          -  Treated with heparin in the previous 48 hours and has a prolonged partial
             thromboplastin time

          -  Baseline platelet count &lt;100,000/mm3

          -  Baseline haematocrit of &lt;0.25

          -  Baseline blood glucose &lt;50 mg/dl or &gt;200 mg/dl

          -  Uncontrolled hypertension defined by a blood pressure, systolic &gt;185 mmHg or diastolic
             &gt;110 mmHg on at least 2 separate occasions at least 10 minutes apart

          -  Patient has hereditary or acquired hemorrhagic diathesis

          -  Gastrointestinal or urinary bleeding within the past 21 days

          -  Arterial puncture in a non-compressible site within the previous 7 days

          -  Another stroke or a serious head injury in the past 6 weeks

          -  Major surgery or serious injury, including other sites than the head, within the
             preceding 14 days

          -  Seizure at the onset of stroke

          -  Acute myocardial infarction (AMI) within the previous 3 weeks

          -  Thrombolytic within the previous 72 hr

          -  Pregnant

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JP006</name>
      <address>
        <city>Akita</city>
        <zip>010-0874</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP021</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP018</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP007</name>
      <address>
        <city>Isesaki</city>
        <zip>374-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP024</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP011</name>
      <address>
        <city>Kawasaki</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP015</name>
      <address>
        <city>Kobe</city>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP022</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP012</name>
      <address>
        <city>Nagoy</city>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP026</name>
      <address>
        <city>Nishinomiya</city>
        <zip>662-0934</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JPO17</name>
      <address>
        <city>Okayama</city>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP002</name>
      <address>
        <city>Sapporo,Hokkaido</city>
        <zip>006-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP001</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP004</name>
      <address>
        <city>Sendai</city>
        <zip>982-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP005</name>
      <address>
        <city>Shibata</city>
        <zip>989-1253</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP014</name>
      <address>
        <city>Suita</city>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP020</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP009</name>
      <address>
        <city>Tokyo</city>
        <zip>145-0065</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP013</name>
      <address>
        <city>Toyota</city>
        <zip>471-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://stroke.ahajournals.org/content/46/9/2549.long</url>
    <description>Publication: &quot;Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke&quot;</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Desmoteplase</keyword>
  <keyword>Japan</keyword>
  <keyword>Safety</keyword>
  <keyword>Stroke</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary plasminogen activator alpha 1, Desmodus rotundus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

